Wednesday, 26 January 2011


Neptune Technologies & Bioressources
Basic Shares: 42.0 million
Fully diluted: 45.48 million


Neptune subsidiary, Acasti Pharma Inc., has added significant heft to its already weighty scientific advisory board with the addition of a world-renowned clinical scientist, Dr. Jean Davignon.

Montreal-based Dr. Davignon's honorifics number in the double digits. That, his stellar reputation and his areas of expertise were what drew Acasti's interest.

His first area of great interest is in Hyperlipidemia, which Wikipedia describes as the condition of abnormally elevated levels of any or all lipids and/or lipoproteins in the blood.

His other area of expertise is in Athersclerosis, defined as the process of progressive thickening and hardening of the walls of arteries from fat deposits on their inner lining. Atherosclerotic heart disease is the leading cause of death in the US.

Acasti is focused primarily on treatments for chronic cardiovascular conditions within the over-the-counter, medical food and prescription drug markets.

"Acasti Pharma continues to demonstrate its dedication to excellence by welcoming Dr. Jean Davignon, a world renowned clinician-scientist in the field Hyperlipidemia and Atherosclerosis," said Dr. Farhad Amiri, Director, Preclinical Studies, Acasti Pharma Inc., in today's news release announcing Dr. Davignon's acceptance of the board seat.

To read all about Dr. Davignon's many, many accomplishments and the other members of Acasti's scientific advisory board please click here.